Bausch + Lomb (BLCO) Expected to Announce Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $1.15 billion for the quarter. Bausch + Lomb has set its FY 2025 guidance at EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the firm posted $0.24 EPS. Bausch + Lomb's quarterly revenue was up 9.1% compared to the same quarter last year. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $12.49 on Wednesday. Bausch + Lomb has a 12-month low of $10.46 and a 12-month high of $21.69. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -13.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.54. The business has a 50 day simple moving average of $14.44 and a 200 day simple moving average of $17.27.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BLCO. HC Wainwright reissued a "buy" rating and issued a $23.00 price target on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Wells Fargo & Company restated an "equal weight" rating and issued a $15.00 price target (down previously from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Stifel Nicolaus lowered their price objective on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research report on Thursday, April 3rd. Bank of America cut their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research note on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $18.82.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.